🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 03/04/2018 | 155,86 | 159,55 | 153,91 | 158,36 | +1,31% | 3,62% | 1.542.300 |
| 02/04/2018 | 161,53 | 161,99 | 153,43 | 156,31 | -4,09% | 5,30% | 1.804.500 |
| 29/03/2018 | 159,83 | 165,51 | 158,76 | 162,98 | +2,13% | 4,22% | 1.527.200 |
| 28/03/2018 | 160,93 | 162,59 | 158,36 | 159,58 | -0,47% | 2,63% | 1.443.700 |
| 27/03/2018 | 167,63 | 168,28 | 159,29 | 160,34 | -3,47% | 5,36% | 1.289.300 |
| 26/03/2018 | 163,85 | 166,35 | 160,27 | 166,10 | +3,21% | 3,71% | 1.327.300 |
| 23/03/2018 | 165,83 | 166,47 | 160,74 | 160,93 | -3,11% | 3,46% | 1.319.400 |
| 22/03/2018 | 167,83 | 170,38 | 165,55 | 166,10 | -2,49% | 2,88% | 1.095.500 |
| 21/03/2018 | 171,94 | 172,42 | 168,60 | 170,34 | -0,66% | 2,22% | 1.050.000 |
| 20/03/2018 | 171,92 | 172,67 | 169,64 | 171,47 | +0,41% | 1,76% | 1.674.300 |
| 19/03/2018 | 174,62 | 175,28 | 168,12 | 170,77 | -2,78% | 4,10% | 1.161.500 |
| 16/03/2018 | 174,84 | 176,42 | 173,25 | 175,66 | +0,97% | 1,81% | 2.462.100 |
| 15/03/2018 | 174,57 | 176,65 | 173,07 | 173,97 | -0,24% | 2,05% | 952.500 |
| 14/03/2018 | 176,15 | 176,48 | 172,82 | 174,38 | -0,33% | 2,08% | 1.036.300 |
| 13/03/2018 | 176,50 | 178,15 | 174,54 | 174,96 | -1,23% | 2,05% | 1.989.500 |
| 12/03/2018 | 176,50 | 178,15 | 174,80 | 177,13 | +0,49% | 1,90% | 1.357.600 |
| 09/03/2018 | 173,26 | 176,31 | 171,76 | 176,26 | +2,55% | 2,63% | 1.415.300 |
| 08/03/2018 | 170,39 | 171,98 | 169,18 | 171,88 | +1,00% | 1,64% | 1.060.700 |
| 07/03/2018 | 167,94 | 170,77 | 167,91 | 170,17 | +0,86% | 1,70% | 1.215.800 |
| 06/03/2018 | 173,33 | 173,85 | 166,05 | 168,72 | -2,56% | 4,50% | 2.176.800 |
| 05/03/2018 | 168,49 | 173,45 | 167,17 | 173,16 | +1,82% | 3,73% | 1.882.400 |
| 02/03/2018 | 163,08 | 170,22 | 161,89 | 170,06 | +2,55% | 5,11% | 2.111.900 |
| 01/03/2018 | 165,68 | 168,00 | 163,61 | 165,83 | -0,12% | 2,65% | 2.028.700 |
| 28/02/2018 | 166,70 | 169,54 | 164,63 | 166,03 | +0,09% | 2,95% | 2.055.500 |
| 27/02/2018 | 168,99 | 170,89 | 165,72 | 165,88 | -2,16% | 3,06% | 1.635.800 |
| 26/02/2018 | 166,92 | 170,36 | 166,03 | 169,54 | +2,19% | 2,59% | 1.779.300 |
| 23/02/2018 | 159,01 | 165,98 | 158,10 | 165,90 | +5,27% | 4,96% | 1.591.100 |
| 22/02/2018 | 161,50 | 162,32 | 157,00 | 157,59 | -0,19% | 3,29% | 1.654.800 |
| 21/02/2018 | 160,63 | 161,72 | 157,83 | 157,89 | -1,92% | 2,42% | 1.160.800 |
| 20/02/2018 | 158,49 | 164,01 | 158,01 | 160,98 | +0,16% | 3,79% | 1.136.400 |